Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation (Q36475213)

14 August 2017

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation (English)

1 reference

cost-effectiveness analysis

14 August 2017

0 references

1 reference

1 reference

1 reference

3

S Claiborne Johnston

1 reference

14 August 2017

Hooman Kamel

1

1 reference

14 August 2017

J Donald Easton

series ordinal

2

1 reference

14 August 2017

Anthony S Kim

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

19 September 2012

1 reference

14 August 2017

1 reference

14 August 2017

79

1 reference

14 August 2017

14

1 reference

14 August 2017

1428-1434

1 reference

Apixaban versus warfarin in patients with atrial fibrillation

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Dabigatran versus warfarin in patients with atrial fibrillation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Risk factors for intracerebral hemorrhage in the general population: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Warfarin, aspirin, or both after myocardial infarction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Inpatient costs of specific cerebrovascular events at five academic medical centers.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Utilization of acute care services in the year before and after first stroke: A population-based study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3525294

Acutely injured patients on dabigatran

21 September 2018

1 reference

12 December 2020

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials

1 reference

12 December 2020

Population trends in the incidence and outcomes of acute myocardial infarction

1 reference

12 December 2020

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

1 reference

12 December 2020

Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1212/WNL.0B013E31826D5FE8

Identifiers

DOI

1 reference

14 August 2017

1 reference

14 August 2017

1 reference